22:28 uur 07-01-2021

Crown Bioscience breidt genomics en Next Generation Sequencing (NGS) -mogelijkheden uit om translationele biomarker-ontdekkingsworkflows te stroomlijnen

SAN DIEGO– ​​(BUSINESS WIRE) – Crown Bioscience, een JSR Life Sciences-bedrijf, kondigde vandaag de uitbreiding aan van hun state-of-the-art NGS-mogelijkheden, samen met de lancering van gepatenteerde NGS-paneldiensten, waardoor farmaceutische partners meer kansen krijgen om een beter begrip van geneesmiddelen mechanisms of action (MOA) en om voorspellende biomarkers te ontwikkelen voor hun kandidaat-geneesmiddelen voor onderzoek.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20210107005802/en/

De nieuwgebouwde, uitgebreide reeks NGS-mogelijkheden biedt klanten een gestroomlijnde multi-omics-workflow van hoogwaardige services, waardoor volledig genomisch begrip mogelijk is, inclusief wereldwijde genexpressie, mutaties en genomische structuren. Dit is een belangrijke aanvulling op CrownBio’s huidige preklinische en translationele diensten, waardoor cliënten meer inzicht krijgen in ziektemechanismen, geneesmiddel-MOA’s en responder patiëntenpopulaties, om uiteindelijk de succesvolle ontwikkeling van effectieve therapieën te versnellen.

Crown Bioscience Expands Genomics and Next Generation Sequencing (NGS) Capabilities To Streamline Translational Biomarker Discovery Workflows

SAN DIEGO–(BUSINESS WIRE)– Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services, providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005802/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.

The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.

“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”

In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.

“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”

These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel. The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:




Media Enquiries:

Richard Pearce

Check out our twitter: @NewsNovumpr